Trial Profile
A retrospective cohort study assessing the incidence of neutropenia and use of prophylactic granulocyte-colony stimulating factor (G-CSF) between nab-Paclitaxel plus gemicitabine and FOLFIRINOX in patients with metastatic pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2016
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 31 May 2016 New trial record
- 25 May 2016 Results presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research